Partner Investment Management L.P. bought a new position in Gritstone Oncology Inc (NASDAQ:GRTS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,092 shares of the company’s stock, valued at approximately $165,000.

Several other institutional investors and hedge funds have also bought and sold shares of GRTS. Riverhead Capital Management LLC purchased a new position in Gritstone Oncology during the third quarter valued at approximately $141,000. Asymmetry Capital Management L.P. purchased a new position in Gritstone Oncology during the third quarter valued at approximately $285,000. Alliancebernstein L.P. purchased a new position in Gritstone Oncology during the third quarter valued at approximately $285,000. Dean Capital Investments Management LLC purchased a new position in Gritstone Oncology during the third quarter valued at approximately $296,000. Finally, Wells Fargo & Company MN purchased a new position in Gritstone Oncology during the third quarter valued at approximately $578,000. Hedge funds and other institutional investors own 43.52% of the company’s stock.

GRTS stock opened at $30.23 on Thursday. Gritstone Oncology Inc has a one year low of $11.22 and a one year high of $29.59.

Gritstone Oncology (NASDAQ:GRTS) last released its quarterly earnings results on Wednesday, November 14th. The company reported ($7.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($6.97). The business had revenue of $0.10 million for the quarter.

In related news, Director Nicholas Simon purchased 333,333 shares of the business’s stock in a transaction on Friday, September 28th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,999,995.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Several brokerages recently commented on GRTS. BTIG Research began coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They set a “buy” rating and a $26.00 price objective for the company. Barclays began coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They set an “overweight” rating and a $25.00 price objective for the company. Goldman Sachs Group began coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued a “neutral” rating and a $18.00 price target for the company. Finally, Cowen began coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued an “outperform” rating for the company.

TRADEMARK VIOLATION WARNING: “Partner Investment Management L.P. Takes $165,000 Position in Gritstone Oncology Inc (GRTS)” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/partner-investment-management-l-p-takes-165000-position-in-gritstone-oncology-inc-grts/2665545.html.

Gritstone Oncology Company Profile

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

See Also: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding GRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gritstone Oncology Inc (NASDAQ:GRTS).

Institutional Ownership by Quarter for Gritstone Oncology (NASDAQ:GRTS)

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.